Eli Lilly & Co. (NYSE:LLY)

Major Pharma Short Sellers Couldn’t Make Up Their Minds Before Failed Trump Health Care Vote

Pharmaceutical companies usually are involved in a lengthy process of getting their drug candidates to market through clinical trials. There is a fair amount of risk involved, should a study ...
Read Full Story »

Short Sellers Back Off Major Pharma

Pharmaceutical companies usually are involved in a lengthy process of getting their drug candidates to market through clinical trials. There is a fair amount of risk involved, should a study ...
Read Full Story »
Prescription drugs

Why Short Sellers Are Making a Massive Bet in Major Pharma

Pharmaceutical companies usually are involved in a lengthy process of getting their drug candidates to market through clinical trials. There is a fair amount of risk involved, should a study ...
Read Full Story »
Pair of dice

Are Short Sellers Doubting Trump by Hiking Bets in Major Pharma?

Pharmaceutical companies usually are involved in a lengthy process in getting their drug candidates to market through clinical trials. There is a fair amount of risk involved, should a study ...
Read Full Story »
Prescription drugs

How Eli Lilly Earnings Won Big on New Drug Sales

Eli Lilly and Co. (NYSE: LLY) released its fourth-quarter earnings report before the markets opened on Tuesday. The company said that it had $0.95 in earnings per share (EPS) and $5.76 ...
Read Full Story »
100 dollar bills

Top 7 Earnings Reports to Look For Tuesday

As January is coming to a close, the fourth-quarter earnings season is beginning to slow, but it's not over yet. 24/7 Wall St. has put together a preview of some of ...
Read Full Story »
Prescription drugs

Short Sellers Run for Cover From Major Pharma

Pharmaceutical companies usually are involved in a lengthy process in getting their drug candidates to market through clinical trials. There is a fair amount of risk involved, should a study ...
Read Full Story »
Jon's friends

Wednesday’s Top Biopharma Winners

The third week of the New Year is halfway over, and a few biopharma companies made massive runs on the day. The health care sector was in trouble over the ...
Read Full Story »
bigger fish

What Eli Lilly Gets With CoLucid Acquisition

Eli Lilly and Co. (NYSE: LLY) has announced it has reached an agreement to acquire CoLucid Pharmaceuticals Inc. (NASDAQ: CLCD) in an all-cash transaction for $46.50 per share, or about ...
Read Full Story »
bull and bear

Top Analyst Upgrades and Downgrades: American Express, JPMorgan, Netflix, Nordstrom, Twitter and Many More

Stocks were indicated to open lower on Tuesday after a three-day weekend. Despite the Dow Jones Industrial Average not yet cracking the elusive 20,000 mark, there is a path for the ...
Read Full Story »
Prescription drugs

Major Pharma Short Interest Declines Ahead of Trump Comments

The short interest data have been released for the December 30 settlement date. Pharmaceutical companies usually are involved in a lengthy process in getting their drug candidates to market through ...
Read Full Story »
investing

JPMorgan Makes Big Changes to US Analyst Focus List for January

That sure didn't take long. And it probably should come as no surprise that many of the top firms we cover here at 24/7 Wall St. are already tweaking their high ...
Read Full Story »
Prescription drugs

Short Interest Rises in Major Pharma

The short interest data have been released for the December 15 settlement date. Pharmaceutical companies usually are involved in a lengthy process in getting their drug candidates to market through ...
Read Full Story »
Doctor, Health (pulse) copy

4 Merrill Lynch Med Tech and Drug Dividend Stocks to Buy With Huge 2017 Potential

One thing that many on Wall Street felt was hampering the pharmaceutical and medical technology stocks was the potential for a Hillary Clinton victory last month. Her harsh rhetoric on drug ...
Read Full Story »
toothpaste

5 Dividend Retirement Stocks to Buy Now and Hold Forever

While interest rates have jumped dramatically recently, much of it has to do with market anticipation on what most experts feel will be a December rate hike by the Federal ...
Read Full Story »